zepbound novo nordisk - Search News

Order byBest matchMost fresh

News

Zepbound beats Wegovy for weight loss

Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial. The data is the first head-to-head trial comparing the wildly popular medicines,

Continue reading

· 3d · on MSN

Zepbound beats Wegovy for weight loss in trial of blockbuster drugs

· 3d · on MSN

Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study

Novo Nordisk's latest bet on obesity pills

Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases.

Continue reading

· 8h · on MSN

Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Sapterna

· 1d · on MSN

Novo Nordisk in pact with Septerna for oral obesity drugs

2d

Zepbound trims more belly fat than Wegovy, study shows

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

MarketBeat on MSN2h

Is It Time to Buy the Dip in Novo Nordisk Stock?

CompanyOverview|NYSE:NVO] Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S (NYSE: NVO) stock is ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results